NCT03153553

Ischemic Preconditioning, Exercise Tolerance and Multiple Sclerosis

Completed NA Last updated 3 January 2024

What this trial tests

NA trial testing Ischemic Preconditioning in Multiple Sclerosis in 22 participants. Completed in 31 December 2019.

Timeline

5 April 2017

Primary endpoint
31 December 2019

31 December 2019

Quick facts

Lead sponsor	Sheffield Teaching Hospitals NHS Foundation Trust
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	other
Enrollment	22
Start date	5 April 2017
Primary completion	31 December 2019
Estimated completion	31 December 2019
Sites	1 location across United Kingdom

Drugs / interventions tested

• Ischemic Preconditioning — full drug profile →
• Sham Intervention

Conditions studied

• Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

Sheffield Teaching Hospitals NHS Foundation Trust

Who can join

18 and older, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Regular physical activity improves aspects such as physical fitness, fatigue, quality of life, gait and also reduces the rate of progression of disability in individuals with Multiple Sclerosis. However, individuals with multiple sclerosis are less physically active than the general population. The determinants of engaging in physical activity for individuals with multiple sclerosis include psychological factors like motivation, self-belief and self-regulatory constructs and physical factors like fatigue, weakness, pain and ataxia.

Ischemic preconditioning is exposure of the body to brief periods of circulatory occlusion and re-perfusion to protect organs against ischemic injury. Recent studies have also shown that ischemic preconditioning also improves exercise performance in healthy participants.

The primary aim and objective of this study is to see whether it is feasible to use Ischemic preconditioning to improve exercise performance in people with Multiple Sclerosis.

The design for the study is a double blind randomized control trial. Forty patients with multiple sclerosis above 18 years of age and who have the ability to walk will be randomized to receive either Ischemic preconditioning or sham intervention. All participants will be identified by MS consultants and nurses from the MS clinic and Neuro Day Case Unit of the Royal Hallamshire Hospital in Sheffield. Participation will involve an additional 2 hours of the patients time.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Effect of remote ischaemic preconditioning on walking in people with multiple sclerosis: double-blind randomised controlled trial.
   Chotiyarnwong C, Nair K, Angelini L, Buckley E, et al · · 2020 · cited 13× · PMID 33681776 · DOI 10.1136/bmjno-2019-000022
2. Effect of Remote Ischemic Conditioning on Heart Rate Responses to Walking in People with Multiple Sclerosis.
   Kai Xin NC, Nair K, Chotiyarnwong C, Baster K, et al · · 2023 · PMID 37092017 · DOI 10.4103/aian.aian_1091_21